Transgelin 2 Antibody - #DF12053

Fig. 1. Aberrantly upregulated expression of TAGLN2 results in the induction of ISGs. A Aberrantly upregulated TAGLN2 protein expression was assessed by IHC analysis in gastric cancer (GC) tissue microarray (TMA) chips containing 75 tumor tissues and their paired normal counterparts. B Cellular TAGLN2 expression in tumor tissues vs. paired normal counterparts was evaluated in the membrane, cytoplasm and nucleus. Distant metastases (M), T stage and overall cancer stage (Stage I~IV) were significantly correlated with TAGLN2 expression in the cytoplasm. C Representative IHC images show that abnormal TAGLN2 expression level increases as GC progresses (Stage I~IV). The results were obtained by multiplying the PP by the IS (immunoreactive score = PP × IS). *P 

Figure 4. | HSP90A, STIP1 and TAGLN‑2 are expressed in B‑AMEVs and T‑AMEVs. (D and E) HSP90A, STIP1 and TAGLN‑2 were present in T‑AMEVs and B‑AMEVs from patients with adenomyosis,but not in those of patients in the control group.

Figure 10. Validation results of TAGLN2 expression in HCC. (a) qRT-PCR analysis of TAGLN2 mRNA expression in 20 pairs of HCC tissues and adjacent non-tumor tissues. (b) Western blot detection of TAGLN2 protein expression and relative quantification in the mean values of three HCC tumor tissues and three neighboring tissues showed elevated TAGLN2 protein expression in HCC tumor tissues. (c) IHC analysis of TAGLN2 stained significantly darker in tumor tissues and had higher protein expression levels than adjacent tissues. (*P < 0.05, **P< 0.01, ***P < 0.001).